Trial Profile
An Open-label, Multi-center Extension Study of Probuphine in Patients With Opioid Dependence
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions
- Acronyms PRO-809
- Sponsors Titan Pharmaceuticals
- 11 Mar 2014 New trial record